MAY 20, 2020
Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release
MAY 19, 2020
Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release
MAY 11, 2020
Convening of another combined General Meeting at a Later Date. Read the Press Release
May 7, 2020
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
April 30, 2020
Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release
April 27, 2020
Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release
APRIL 21, 2020
Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
April 7, 2020
Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19. Read the Press Release
April 7, 2020
Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
April 7, 2020
Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release